Stay updated on REOLYSIN in KRAS Mutant CRC Clinical Trial

Sign up to get notified when there's something new on the REOLYSIN in KRAS Mutant CRC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the REOLYSIN in KRAS Mutant CRC Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The completed study record for a Phase 1 trial of REOLYSIN® with FOLFIRI and bevacizumab in KRAS-mutant metastatic colorectal cancer is displayed, including its treatment plan, eligibility criteria, study outcomes, and record dates.
    Difference
    49%
    Check dated 2026-11-07T12:24:56.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The site footer’s revision label changes from v3.7.2 to v3.8.0, while the study page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T13:22:23.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    A site-wide banner announces that NIH is transitioning from the term “Artificial Intelligence” to “Super Intelligence.” It appears above the unchanged 403 error page.
    Difference
    1%
    Check dated 2026-10-24T13:41:56.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The site revision identifier changed from v3.7.1 to v3.7.2 while the page continued to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-17T14:35:32.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The footer identifies the site revision as v3.7.1 instead of v3.7.0.
    Difference
    0.2%
    Check dated 2026-10-10T14:43:36.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    The study page now renders a 403 Forbidden error instead of the study record content, making the page inaccessible and preventing access to the trial details.
    Difference
    18%
    Check dated 2026-09-19T22:06:29.000Z thumbnail image

Stay in the know with updates to REOLYSIN in KRAS Mutant CRC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the REOLYSIN in KRAS Mutant CRC Clinical Trial page.